WEX is developing a new class of non-opioid analgesics. The Company’s proprietary platform is Halneuron™ (TTX), a highly selective sodium channel blocker. WEX’s lead product Halneuron™ based on TTX is in Phase III clinical development for the treatment of cancer related pain and starting Phase III for chemotherapy induced neuropathic pain.
WEX has conducted 15 clinical trials with TTX, with more than 700 subjects treated to date.
WEX is a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”), listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, and water businesses and investment in various financial and investment products. CKLS is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.